Preneoplasia-associated expression of calcyclin and of binding sites for synthetic blood group A/H trisaccharide--exposing neoglycoconjugates in human lung.
Development of preneoplastic lesions in human lung is supposed to be accompanied with alterations of distinct biochemical features which might functionally be crucial for this alteration. To contribute to the definition of such determinants in peripheral lung parenchyma, the files of the Department of Pathology, Thoraxklinik, (a total of 2890 cases) were screened for respective tissue specimens. Seventy one cases with complete clinical documentation were found and an age-, sex-, and disease-matched control group was formed. When compared to control group patients, especially the tumor free cases with preneoplastic aberrations revealed a history of exposure to external noxes. Several probes with assumed relevance were tested with the panel of specimens for both groups, focussing on comparative analysis of alveolar lining cells. In addition to labelled neoglycoconjugates which include tissue lectin-seeking probes that expose mono-, di- and blood group-related trisaccharides, presence of calcium- and annexin-binding calcyclin, of complement component C5b, of the lymphokine macrophage migration inhibitory factor, and of ligands of the serum amyloid P component was evaluated. Compared to normal cells at the alveolar surface in controls, the preneoplastic cells displayed an apparent down-regulation of expression of A/H-trisaccharide-specific binding sites and an upregulation of expression of calcyclin. These three characteristics correlated with the phenotypic alterations and encourage further studies to elucidate the functional significance of reduced expression of the glycoligand-specific sites and the presence of this member of the S100-family of Ca(2+)-binding proteins.
Kayser
K
K
Department of Pathology, Thoraxklinik, Heidelberg, Germany.
André
S
S
Bovin
N V
NV
Zeng
F Y
FY
Gabius
H J
HJ
D000328:Adult; D000368:Aged; D001665:Binding Sites; D001789:Blood Group Antigens / Q000378:metabolism*; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D018797:Cell Cycle Proteins; D005260:Female; D006001:Glycoconjugates / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D011650:Pulmonary Alveoli / Q000473:pathology; D012189:Retrospective Studies; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins; D014312:Trisaccharides / Q000378:metabolism*
D001789:Blood Group Antigens; D002135:Calcium-Binding Proteins; D018797:Cell Cycle Proteins; D006001:Glycoconjugates; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins; D014312:Trisaccharides; C055351:S100A6 protein, human